Melancholic Symptoms During Concurrent Olanzapine and Fluoxetine

References

• Potenza MN, Wasylink S, Longhurst JO, Epperson CN, McDougleOlanzapine augmentation of fluoxetine in thetreatment of refractory obsessive-compulsive disorder. J Clin Psychopharmacol 1998; 18:423–424
   PubMedGoogle Scholar
• Potenza MN, Wasylink S, Longhurst JG, Epperson CN, McDougle CJ: Olanzapine augmentation of fluoxetine in the treatment of trichotillomania. Am J Psychiatry 1998; 155: 1299–1300
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Shelton R, Tohen M, Stahl S, Jacobs T, Buras W, Spencer KA, Gannon KS: The study of olanzapine com-bined with fluoxetine in patients with treatment-resistant major depressive disorder without psychotic features. Poster Presentation, 2nd annual meeting of the College of Psychiatric and Neurologic Pharmacists, Nevada, March 25–28,1999
   Google Scholar
• Weisler RH, Ahearn EP, Davidson JR, Wallace CD: Ad-junctive use of olanzapine in mood disorders: five case reports. Ann Clin Psychiatry 1997; 9:259–262
   Google Scholar
• Centorrino F, Baldessarini RI, Kando I, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG: Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. American Journal of Psychiatry 1994; 151:123–125
   PubMed Web of Science ®Google Scholar
• Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG: Serum levels of clozapine and norclo-zapine in patients treated with selective serotonin reuptake inhibitors. American Journal of Psychiatry 1996; 153:820–822
   PubMed Web of Science ®Google Scholar
• Shen WW: An updated review of the metabolism of clozapine and olanzapine. Annals of Clinical Psychiatry 1999; 11: 145–158
   Google Scholar
• Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Ceri-mele BJ, Swanson SP, Hamman MA, Wrighton SA: Identifi-cation of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. The Journal of Pharmacology and Experimental Therapeutics 1996; 276:658–666
   PubMed Web of Science ®Google Scholar
• Harvey AT, Preskorn SH: Cytochrome P450 enzymes: inter-pretation of their interactions with selective serotonin reup-take inhibitors. Part II. J Clin Psychopharmacol 1996; 16: 345–355
   PubMed Web of Science ®Google Scholar
• Zyprexa Product Information. Eli Lilly & Co. Sept. 24,1996
   Google Scholar
• Olesen OV, Linnet K: Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Therapeutic Drug Monitoring 1999; 21:87–90
   PubMed Web of Science ®Google Scholar
• Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S: Fluovoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45:1211–1214
   PubMed Web of Science ®Google Scholar
• Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA: In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Brit J Clin Pharmacol 1996; 4:181–186
   Google Scholar
• Mihara K, Otani K, Ishida M, Yasui N, Suzuki A, Ohkubo T, Osanai T, Kaneko S, Sugawara K: Increases in plasma concentration of m-chlorophenylpiperazine, but not trazo-done, with low-dose haloperidol. Therapeutic Blood Monitor-ing 1997; 19:43–45
   Google Scholar
• Otani K, Ishida M, Kaneko S, Mihara K, Ohkubo T, Osanai T, Sugawara K: Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabo-lite, m-chlororphenylpiperazine. Therapeutic Blood Monitor-ing 1996; 18:164–167
   Google Scholar
• Rotzinger S, Fang J, Baker G: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metabolism and Disposition 1998; 26:572–575
   PubMed Web of Science ®Google Scholar
• Metz A, Shader RI: Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol 1990; 5:191–194
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Cole JO, Glass L: Possible trazodone potenti-ation of fluoxetine: a case series. J Clin Psychiatry 1992; 53:83–85
   PubMed Web of Science ®Google Scholar
• Chouinard G, Leflto-Singh K, Teboul E: Metabolism of anxio-lytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 1999; 19:533–552
   PubMed Web of Science ®Google Scholar
• Gammans RE, Mayol RF, LaBudde JA: Metabolism and dis-position of buspirone. Am J Med 1986; 80 (suppl B):41–51
   Google Scholar
• Jajoo HK, Mayol RE, LaBudde JA, Blair IA: Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989; 17:634–40
   PubMed Web of Science ®Google Scholar
• Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ: Plasma buspirone concentrations are greatly increased by erythromy-cM and itraconazole. Clinical Pharmacology & Therapeutics 1997; 62:348–354
   PubMed Web of Science ®Google Scholar
• Piergies AA, Sweet J, Johnson M, Roth-Schechter BF, Allard S: The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. International Journal of Clinical Pharmacology and Therapeutics 1996; 34:178–183
   PubMed Web of Science ®Google Scholar
• Caccia S: Metabolism of the newer antidepressants: an over-view of the pharmacological and pharmacokinetic implica-tions. Clin Pharmacokinet 1998; 34:281–302
   PubMed Web of Science ®Google Scholar
• Benazzi F: Serotonin syndrome with mirtazapine-fluoxetine combination. Int J Geriat Psychiatry 1998; 13:495–496
   PubMed Web of Science ®Google Scholar